AiRuiKang (dalpiciclib) - Jiangsu Hengrui Pharma
ifebemtinib (IN10018) - InxMed
IN10018 in Combination With Dalpiciclib for Progressive Meningiomas (clinicaltrials.gov) - Aug 8, 2026 - P1 | N=24 | Recruiting | Sponsor: Capital Medical University | Not yet recruiting ➔ Recruiting 
Enrollment open • Brain Cancer • Meningioma • Oncology • Solid Tumor
http://clinicaltrials.gov/ct2/show/NCT07652762
 
Aug 8, 2026
 
Prev Next